Oncolytic virus (OV), either naturally occurring or genetically modified, is relatively a new class of anti-cancer agent that selectively replicates in cancer cells (sparring healthy cells) while inducing anti-tumor immunity (i.e., in situ vaccine effect). Among all OVs, oncolytic herpes simplex virus (oHSV) armed with an immunostimulatory GM-CSF (designated T-VEC) is approved for the treatment of advanced melanoma. Besides oHSV, at least 15 other OVs are under clinical development and many more are being tested preclinically either alone or in combination with other anti-cancer agents or immunotherapies. T-VEC approval in 2015 was a crucial turning point that significantly fueled the field of OV-based cancer immunotherapy as evidenced by hundreds of OV trials that are currently running to combat cancer. Although oHSV is the furthest and a leading oncolytic agent in the clinic, it has limitations in treating advanced metastatic diseases, and, similarly, each OV has its own strengths/limitations, indicating further improvements are needed to obtain long-term treatment solutions for cancer patients. In this Special Issue on “Oncolytic Viruses in Cancer Therapy”, our goal is to provide a current understanding of OV in the field of cancer immunotherapy that includes current trend, future opportunities, and challenges to fight cancer.
Dr. Dipongkor Saha
Manuscripts should be submitted via our online editorial system at https://imr.propub.com by registering and logging in to this website. Once you are registered, click here to start your submission. Manuscripts can be submitted now or up until the deadline. All papers will go through peer-review process. Accepted papers will be published in the journal (as soon as accepted) and meanwhile listed together on the special issue website. Research articles, reviews as well as short communications are preferred. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office to announce on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts will be thoroughly refereed through a double-blind peer-review process. Please visit the Instruction for Authors page before submitting a manuscript. The Article Processing Charge (APC) in this open access journal is 2500 USD. Submitted manuscripts should be well formatted in good English.
- Oncolytic Viruses as an Adjunct to Immune Checkpoint InhibitionJacob Ripp, Stijn Hentzen, Anwaar SaeedFront. Biosci. (Landmark Ed) 2022, 27(5), 151; https://doi.org/10.31083/j.fbl2705151(This article belongs to the Special Issue Oncolytic Viruses in Cancer Therapy)85Download179Views
- Oncolytic viruses in melanomaCamille Robinson, Maria M Xu, Smita K Nair, Georgia M Beasley, Kristen E RhodinFront. Biosci. (Landmark Ed) 2022, 27(2), 63; https://doi.org/10.31083/j.fbl2702063(This article belongs to the Special Issue Oncolytic Viruses in Cancer Therapy)86Download232Views